Physician profile
Sunitha A Bharadia
NPI 1669447355
$15,013.46
in general payments reported to CMS, 2019-2025
64 companies · $2,748 in 2025
The $2,748 reported for 2025 was more than what 82% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,870 · 2020: $1,174 · 2021: $2,039 · 2022: $2,484 · 2023: $2,226 · 2024: $2,472 · 2025: $2,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,416 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,416.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,321.26 | 2021-2025 | Vraylar, Botox, Ubrelvy |
| Ucb, INC. | $1,789.28 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Acadia Pharmaceuticals INC | $853.40 | 2019-2025 | Nuplazid, Daybue |
| Mdd US Operations, LLC | $639.41 | 2019-2025 | Gocovri, Gocovri |
| Merck Sharp & Dohme LLC | $536.08 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Neurocrine Biosciences, INC. | $529.98 | 2020-2025 | Ingrezza |
| Emd Serono, INC. | $511.84 | 2019-2025 | |
| Lundbeck LLC | $481.37 | 2021-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $460.75 | 2019-2025 | |
| Allergan, INC. | $442.79 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $435.46 | 2021-2025 | Lifevest |
| Sk Life Science, INC. | $394.88 | 2021-2025 | |
| Lilly USA, LLC | $375.11 | 2019-2024 | Amyvid, Emgality |
| Ipsen Biopharmaceuticals, INC | $350.94 | 2019-2025 | Dysport |
| Amgen INC. | $315.80 | 2019-2023 | Repatha |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Bharadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.